Cipla announced the acquisition of a novel and patented anti-infective product, Elores, from
Venus Remedies (VRL) for the Indian market to further strengthen its presence in the
branded Indian critical care space and as a part of its agenda to contribute to the fight against
Anti-Microbial Resistance (AMR).
Elores is a novel combination of Ceftriaxone (a third generation beta-lactam cephalosporin), Sulbactam (a beta-lactamase inhibitor) and Disodium EDTA (an Antibiotic Resistance Breaker) indicated for the treatment of life threatening infections caused by gram-negative bacteria. It preserves the efficacy of the antibiotic using appropriate Antibiotic Resistance Breakers (ARBs). The product was launched in India across select tertiary care hospitals in the country in 2013 after approval from the Drug Controller General of India.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
